Abstract
The α7-nAChR plays critical roles in numerous organs and cells by regulating highly organ and cell typespecific functions. In this special issue different Authors have contributed to clarify the different roles played by the α7- nAChR. Post-translational processes such as receptor “underactivation” or “overactivation” are associated in the central nervous system with brain disorders including neurodegeneration, while also contributing to the regulation of nonneuronal cells and cancers derived from them. Current advances in the knowledge of α7-nAChR biology encourage the exploitation of this receptor as a therapeutic target for a variety of diseases, including Alzheimer’s, disease, Parkinson’s disease, cognitive decline, pain and cancer.
Keywords: α7-nAChR, biological activity, future perspectives, new drugs, toxins
Current Drug Targets
Title:A New “Era” for the α7-nAChR
Volume: 13 Issue: 5
Author(s): Patrizia Russo, Alessio Cardinale, Hildegard Shuller
Affiliation:
Keywords: α7-nAChR, biological activity, future perspectives, new drugs, toxins
Abstract: The α7-nAChR plays critical roles in numerous organs and cells by regulating highly organ and cell typespecific functions. In this special issue different Authors have contributed to clarify the different roles played by the α7- nAChR. Post-translational processes such as receptor “underactivation” or “overactivation” are associated in the central nervous system with brain disorders including neurodegeneration, while also contributing to the regulation of nonneuronal cells and cancers derived from them. Current advances in the knowledge of α7-nAChR biology encourage the exploitation of this receptor as a therapeutic target for a variety of diseases, including Alzheimer’s, disease, Parkinson’s disease, cognitive decline, pain and cancer.
Export Options
About this article
Cite this article as:
Patrizia Russo, Alessio Cardinale, Hildegard Shuller , A New “Era” for the α7-nAChR , Current Drug Targets 2012; 13 (5) . https://dx.doi.org/10.2174/138945012800398946
DOI https://dx.doi.org/10.2174/138945012800398946 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics Peeking into the Black Box: How Cytokine Antibody Arrays Shed Light on Molecular Mechanisms of Breast Cancer Development and its Treatment
Current Proteomics Anticancer Properties of Amino Acid and Peptide Derivatives of Mycophenolic Acid
Anti-Cancer Agents in Medicinal Chemistry The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View
Current Medicinal Chemistry Targeting Tumor Lymphangiogenesis: An Update
Current Medicinal Chemistry Exosomes and Lung Cancer: Roles in Pathophysiology, Diagnosis and Therapeutic Applications
Current Medicinal Chemistry Malignant Mesothelioma: Cell Survival Pathways and Radiation Therapy
Current Respiratory Medicine Reviews The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Structure-Activity Relationship of Supramolecular Compounds in Drug Delivery
Mini-Reviews in Organic Chemistry Recent Patent-Based Perspective on Diagnostic and Therapeutic Interventions in Malignant Mesothelioma: Is Drug Repositioning Knocking on the Door?
Recent Patents on Anti-Cancer Drug Discovery TNF-Related Apoptosis-Inducing Ligand (TRAIL) as a Pro-Apoptotic Signal Transducer with Cancer Therapeutic Potential
Current Pharmaceutical Design Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Current Chemical Biology Cancer Stem Cells Switch on Tumor Neovascularization
Current Molecular Medicine Ewing Sarcoma Family Tumors: Past, Present and Future Prospects
Current Cancer Therapy Reviews Apoptosis and Apoptosis-Based Therapy in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development
Current Pharmaceutical Design Advances in Imaging Gene-Directed Enzyme Prodrug Therapy
Current Pharmaceutical Biotechnology Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy
Current Drug Metabolism Anticancer Therapeutic Strategies Based on CDK Inhibitors
Current Pharmaceutical Design